Capstan Medical Secures Financing for Robotic Platform to Treat Heart Valve Disease

December 11, 2024—Capstan Medical, a developer of robotic-enabled minimally invasive solutions to address heart valve disease, announced the closing of an oversubscribed $110 million Series C financing round to advance the company’s structural heart technology.

According to Capstan, its minimally invasive solution seeks to bring together heart valve implants and catheter technology, enabled through a robotic platform, to treat a broad set of patients. With the new funding, the company will continue to execute on its plan for expanded clinical and development work leading to upcoming pivotal trials.

Capstan Medical, which was founded in 2020, has a team of more than 75 employees with heart valve, implant delivery, and robotics expertise across engineering, operations, clinical, and regulatory areas, noted the press release.

The company stated that the financing round was led by Eclipse with participation from existing investors Yu Galaxy and Intuitive Ventures, and new investment from Gideon Strategic Partners.

“Percutaneous intervention has the opportunity to dramatically increase the treatment options for the millions of people suffering from heart valve disease,” commented Capstan Medical’s CEO Maggie Nixon in the press release. “At Capstan, we believe that our robotic platform with a full portfolio of implants can uniquely address the urgent needs of this underserved patient population. We have pulled together the right people at the right time to make this happen and are energized by the incredible support of our investors.”